Skip to main content
ASTAL LABORATORIES LIMITED logo

ASTAL LABORATORIES LIMITED — Investor Relations & Filings

Ticker · 512600 ISIN · INE307N01014 LEI · 8945004HO2WCBQ0CJ976 BSE.NS Manufacturing
Open in API
Filings indexed 442 across all filing types
Latest filing 2025-11-14 Regulatory Filings
Country IN India
Listing BSE.NS 512600

About ASTAL LABORATORIES LIMITED

https://miel.co.in/

Astal Laboratories Limited is a pharmaceutical organization engaged in the development, manufacturing, and marketing of a diverse range of pharmaceutical formulations. The company's product portfolio encompasses various dosage forms, including tablets, capsules, liquid orals, and topical preparations. It operates across several therapeutic categories, such as anti-infectives, analgesics, and gastrointestinal treatments. Astal Laboratories prioritizes quality control and adheres to established manufacturing standards to ensure the safety and efficacy of its products. The company focuses on providing accessible healthcare solutions through a robust distribution network and a commitment to research-driven formulation development.

Recent filings

Filing Released Lang Actions
Submission of outcome of the Board Meeting held on 14th November, 2025.
Regulatory Filings
2025-11-14 English
Astal Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve 1. To Consider and Approve ....
Regulatory Filings Classification · 95% confidence The document is a formal notice from Astal Laboratories Limited to the stock exchange (BSE Limited) informing about an upcoming Board Meeting scheduled for November 14, 2025. The purpose of the meeting is to consider and approve the unaudited standalone financial results for the quarter and half year ended September 30, 2025, along with the Limited Review Report of the auditors. The document also mentions the closure of the trading window for insiders as per SEBI regulations. The document is short (2458 characters) and serves as an intimation or announcement of a board meeting and upcoming financial results approval, not the financial results report itself. It does not contain actual financial data or detailed analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2025-11-10 English
Submission of intimation of approval of amendment in MOA.
Share Issue/Capital Change Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, addressed to the Bombay Stock Exchange. It reports the approval by shareholders at an Extraordinary General Meeting (EGM) for the alteration of the Capital Clause V of the Memorandum of Association, specifically an increase in the authorised share capital. The document is a formal announcement of a capital change event, not a detailed financial report or a full filing. It is short (2446 characters) and serves as a notification of a capital structure change. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2025-11-09 English
Submission of Intimation of Voting results and Scrutinizer''s Report.
Regulatory Filings
2025-11-07 English
Submission of Outcome of the EGM.
Regulatory Filings
2025-11-06 English
Submission of newspaper Advetisement.
Regulatory Filings
2025-11-05 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.